Medulloblastoma is the most common malignant brain tumor in childhood. It is related to unsatisfactory survival rates and the development of causal therapies is highly desired. We show here that expression of the transcription factor FoxM1 may serve as an independent prognostic marker which easily allows clinicians to individually adjust therapy strategies. We further show that FoxM1 is essential for the growth of medulloblastoma cells and may serve as therapeutic target. Last, the antibiotic Siomycin A proved to successfully downregulate FoxM1 and to inhibit tumor cell growth. Our studies may therefore serve as a basis for clinical trials including expression of FoxM1
FoxM1 in medulloblastoma
Conclusions: FoxM1 may be used as an additional prognostic marker and may represent a potential novel target to treat patients suffering from medulloblastoma.
Introduction
Medulloblastoma is the most common malignant brain tumor in childhood with a fiveyear overall survival of 66% (1) . State-of-the-art treatment combines surgery, craniospinal irradiation, and multiple chemotherapeutics with severe sequelae of toxic side effects (2) (3) (4) . The development of novel treatment options is therefore urgently needed. Medulloblastoma is a heterogeneous disease with 6 subgroups that differ with respect to histology, molecular expression profiles, genetics and clinical outcome (5) . One of these subgroups is associated with a constitutive activation of the Sonic hedgehog signaling pathway, which may for instance be caused by mutations of genes encoding the Hedgehog receptors Patched or Smoothened (6, 7) . While the cellular origin of medulloblastoma is uncertain for most of the 6 subgroups, tumors associated with pathological Hedgehog signaling have recently been demonstrated to arise from cerebellar granule neuron precursors (8) . During normal development, these precursors extensively proliferate due to a physiological stimulation by Sonic hedgehog (9) until they migrate away from their mitotic niche in the external granule cell layer and differentiate at postnatal stages (10) . While the mechanisms of differentiation in cerebellar granule neurons are not yet clearly understood, it is evident that their cell cycle progression is dependent on FoxM1 (11), which is a target gene of Hedgehog signaling (12, 13) .
FoxM1 (previously known as HFH-11B, MPP2 or Trident) is a member of the Forkhead family of transcription factors that share homology within the wingedhelix/Forkhead DNA-binding domain (14, 15) . FoxM1 is predominantly expressed in fetal tissues but its expression may be maintained in proliferating adult tissues (15, Research.
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Author Manuscript Published OnlineFirst on September 14, 2011; DOI: 10.1158/1078-0432.CCR- 5 FoxM1 in medulloblastoma 16 ). FoxM1 is a key regulator of the transition from G1 to S phase by activating genes required for cell cycle progression such as Cdc25B, cyclin B1, Aurora B kinase, and Polo-like kinase 1 (14, 17) . FoxM1 is also essential for chromosome segregation (16, 18) , and depletion of FoxM1 leads to a failure to enter S phase and impairs proper M-phase completion with subsequent mitotic catastrophe (15, 17, 19) .
Increased levels of FoxM1 of expression have been detected in many different types of human cancer such as basal cell carcinomas, breast cancer, glioblastomas, lung cancers, pancreas and prostate cancer (13, (19) (20) (21) (22) . Within this context, FoxM1 has not only been identified as a prognostic marker (22), but its expression has also been demonstrated to be required for the growth of lung cancer (20), prostate carcinomas 
Material and Methods

Tissue samples and cell lines
A total of 43 formalin-fixed paraffin-embedded surgical tumor samples from patients with medulloblastoma were analyzed. Inclusion of patients in the study was unbiased
Research. Münster (all Germany). Nineteen children were treated in prospective multicenter trials as described: (1) HIT 2000 trial (n=9; stratification of risk-adapted treatment according to age and metastasis stage into 4 different treatment arms with combination of postoperative chemotherapy and/or radiotherapy and/or maintenance chemotherapy) (2) HIT'91 trial (n=6; randomized trial of postoperative chemotherapy followed by craniospinal radiotherapy versus postoperative craniospinal radiotherapy followed by maintenance chemotherapy) (24); (3) HIT-MED'99 (n=2; stratification of riskadapted treatment according to age and metastasis stage into 4 different treatment arms); (4) HIT'88 trial (n=1; preradiation chemotherapy and radiotherapy) (25) ; (5) HIT'87 trial (n=1; systemic interval chemotherapy until craniospinal radiotherapy was applied at 3 years of age or at relapse) (26) . The median age was 9.3 years (range, 0.6 -45.6 years). The median follow-up of survivors was 53 months (range, 22.2 -175.6 months). 16 patients succumbed to their disease, 25 were alive as of January were collected on an Olympus IX50 microscope. Images from cell culture experiments were taken using a confocal laser scanning microscope (Zeiss, Germany).
Cell culture
All cell lines were grown in DMEM medium containing 10% fetal calf serum and 1% glutamine at 37°C and 5% CO 2 in a humidified atmosphere. Lentiviral particles for 
Statistical analysis
For analysis of the expression data and cell viabilities, the Mann-Whitney-U-test was used to compare the median of two groups. To calculate the fraction of tumor cells labeled with antibodies against FoxM1 and Ki67, at least 500 tumor cells were counted for each tumor. Correlation of two paired data sets was done with the Spearman correlation. Fractions of mitotic cells with abnormal spindles in different experimental conditions were compared using the Fisher's exact test. The KaplanMeier method was used to estimate survival, and log-rank-tests were used to compare survival between the respective groups. For all tests, a p-value<0.05 was considered significant. Analyses were performed using Prism 5 (Graphpad, USA) except FoxM1 in medulloblastoma for multivariate analyses with Cox regression models that were done using PASW statistics 18 (IBM, USA).
Results
Expression pattern of FoxM1 in human medulloblastoma tumor samples
We have previously performed in situ hybridizations to demonstrate expression of FoxM1 in murine cerebellar tissue (11) . In particular, we found that FoxM1 is ex- Table 1 . Expression of FoxM1 protein was detectable in all analyzed medulloblastomas and was restricted to the tumor cell nuclei (Fig. 1C) . Tumors displayed a median expression of 6.95%, ranging between 2.44% and 30.7% of nuclei binding antibodies against FoxM1 (Fig. 1D) . As shown in Figure 1C In order to confirm these results in an independent cohort, we re-analyzed available micro-array data from 130 medulloblastoma patients with documented clinical followup (5). Here, patients were sorted on the basis of expression of FOXM1 and subsequently dichotomized on the basis of a series of FOXM1 expression levels. Log-rank
Research. 
12
FoxM1 in medulloblastoma significance was calculated for each cutoff and the best p-value out of the sequence was used for further analysis. As shown in Figure 2B , patients suffering from tumors with high levels of FOXM1 (n=44) had a significantly worse outcome compared to patients with tumors that displayed only low levels of FOXM1 (n=86; log-rank test, p=0.0055). The same cohort of patients was originally used to identify a subgroup of patients with a distinct genetic fingerprint that drives poor clinical outcome (5). This "c1" subgroup is characterized genetically by CMYC copy number gains and transcriptionally by enrichment of photoreceptor pathways and increased miR-183_96_182 expression. Further parameters that were previously found to predict the outcome of patients with medulloblastoma included Wnt pathway activation (29) , large cell/anaplastic histology (28) and the presence of metastases (4) . In order to evaluate whether the prognostic value of FOXM1 is independent of these characteristics, we performed uni-and multivariate analyses using a Cox regression model. As demonstrated by univariate Cox-regression analyses, expression of FOXM1 again turned out as a prognostic marker in patients with medulloblastoma (p=0.008), similar to LC/A histology (p=0.008) and a "c1" molecular profil (p=0.009, Fig. 2C ). Although Wnt activation and metastatic disease did not reach statistical significance in univariate analyses of this series (Fig. 2C ), they were included into the multivariate model to obtain estimates of Hazard ratios adjusted for them (Fig. 2D) . Using this multivariate model, we found that expression of FOXM1 is an independent prognostic marker for patients with medulloblastoma (hazard ratio, 2.24; 95% confidence interval, 1.05-4.77; p=0.037; Fig. 2D ).
Knock down of FoxM1 reduces medulloblastoma cell growth by induction of mitotic catastrophe
In order to unravel the functional impact of FoxM1 in medulloblastoma, we aimed to knock down FOXM1 expression in 4 permanent human medulloblastoma cell lines (D425med, DAOY, R300, and UW228) and measured cell viability in control and in knockdown conditions. As shown in Figure 3A , all medulloblastoma cell lines expressed high levels of FoxM1 protein when transduced with lentiviral particles containing mock sequences. However, transduction with lentiviral particles containing two different shRNA sequences against FOXM1 resulted in a dramatic decrease in FoxM1 protein expression, as measured by Western blot analysis ( Figure 3A) . Remaining levels of FoxM1 expression ranged between 9.23%-47.66% compared to protein levels of mock transduced cells. In order to investigate whether high expression of FoxM1 might be a general phenomenon associated with proliferating cells, we further analyzed FoxM1 expression in HEK293T cells, and found that this cell line express only very low levels of FoxM1 (Fig. 3A) . Cell viability was measured using 3- (Fig. 3B) . Interestingly, knock down of FoxM1 in HEK293T cells did not affect cell viability significantly (Fig. 3B) . Mechanistically, Western blot analysis revealed that cleaved Caspase 3 was upregulated in all FoxM1-depleted medulloblastoma cell lines, but not in HEK293T cells with a knock down of FoxM1 (Fig.   3C ). Upregulation of Caspase 3 may occur as a part of mitotic catastrophe (30) which had previously been described both for FoxM1-deficient cerebellar granule neurons (Fig. 4D) . Together, we suggest that knock down of FoxM1 in medulloblastoma cells results in mitotic catastrophe as shown by enhanced expression of cleaved caspased 3, nuclear translocation of Cyclin B1 and abnormal cell spindles.
Siomycin A reduces expression levels of FoxM1 and recapitulates effects of FoxM1 knock down in medulloblastoma cells
The antibiotic thiazole compound Siomycin A has previously been reported to represent a specific inhibitor of FoxM1 (33). We therefore tested whether Siomycin A was able to reduce levels of FoxM1 in medulloblastoma cells and hence to inhibit tumor cell growth. As shown in Figure 5A , treatment of human medulloblastoma cell lines D425med, DAOY, R300, and UW228 with Siomycin A resulted in a decrease of FoxM1 in medulloblastoma levels to 48.20% (mean) in medulloblastoma and HEK293T cells (Fig. 5A) . Next, cell viability was determined using MTT assays and showed a dose-dependent Siomycin A-induced reduction of cell numbers in all treated human medulloblastoma cell lines (Fig. 5B) . Interestingly, growth of HEK293T was not significantly affected by Siomycin A, suggesting that Siomycin A is not generally anti-proliferative or toxic (Fig. 5B ). FoxM1 in medulloblastoma 6D). Taken together, our data suggest that Siomycin A is able to significantly downregulate expression of FoxM1 and inhibits the growth of medulloblastoma cells.
High concentrations of Siomycin
Discussion
We report here that FoxM1 is highly expressed in human medulloblastoma and that it proved to be a prognostic marker both in a training set of 43 tumors that were ana- Research. 
